Glomerulonephritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Glomerulonephritis is a disease of the kidney, characterized by inflammation of the glomeruli. Some factors that increase the chances of getting glomerulonephritis include a family history of glomerulonephritis, the presence of a known cause of glomerulonephritis, and high blood pressure.
The Glomerulonephritis pipeline market research report provides comprehensive information on the therapeutics under development for Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects.
Key Targets in the Glomerulonephritis Pipeline Products Market
The key targets in the Glomerulonephritis pipeline products market are Complement Factor D, Endothelin 1 Receptor, Mannan Binding Lectin Serine Protease 2, Tumor Necrosis Factor Ligand Superfamily Member 13, Complement C3, Complement Factor B, C-C Chemokine Receptor Type 2, Short Transient Receptor Potential Channel 5, Apolipoprotein L1, CD40 Ligand, and others.
Glomerulonephritis Pipeline Products Market Analysis by Targets
For more target insights, download a free report sample
Key Mechanisms of Action in the Glomerulonephritis Pipeline Products Market
The key mechanisms of action in the Glomerulonephritis pipeline products market are Complement Factor D Inhibitor, Endothelin 1 Receptor Antagonist, Mannan Binding Lectin Serine Protease 2 Inhibitor, Tumor Necrosis Factor Ligand Superfamily Member 13 Inhibitor, Complement C3 Inhibitor, Complement Factor B Inhibitor, C-C Chemokine Receptor Type 2 Antagonist, Short Transient Receptor Potential Channel 5 Blocker, Apolipoprotein L1 Inhibitor, CD40 Ligand Inhibitor, and others.
Glomerulonephritis Pipeline Products Market Analysis by Mechanisms of Action
For more mechanisms of action insights, download a free report sample
Key Routes of Administration in the Glomerulonephritis Pipeline Products Market
The key routes of administration in the Glomerulonephritis pipeline products market are oral, subcutaneous, intravenous, intravitreal, intramuscular, intravenous drip, nasogastric, and parenteral.
Glomerulonephritis Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the Glomerulonephritis Pipeline Products Market
The key molecule types in the Glomerulonephritis pipeline products market are small molecule, monoclonal antibody, fusion protein, synthetic peptide, recombinant protein, antisense RNAi oligonucleotide, gene-modified cell therapy, polymer, recombinant enzyme, and antibody.
Glomerulonephritis Pipeline Products Market Analysis by Molecule Types
For more molecule type insights, download a free report sample
Major Companies in the Glomerulonephritis Pipeline Products Market
Some of the major companies in the Glomerulonephritis pipeline products market are Chinook Therapeutics Inc, Alexion Pharmaceuticals Inc, Visterra Inc, Wuhan LL Science and Technology Development Co Ltd, Apellis Pharmaceuticals Inc, Goldfinch Bio Inc, Omeros Corp, Vertex Pharmaceuticals Inc, Anagenics Ltd, and Calliditas Therapeutics AB.
Glomerulonephritis Pipeline Products Market Analysis by Companies
To know more about major companies, download a free report sample
Glomerulonephritis Pipeline Products Market Report Overview
| Key Targets | Complement Factor D, Endothelin 1 Receptor, Mannan Binding Lectin Serine Protease 2, Tumor Necrosis Factor Ligand Superfamily Member 13, Complement C3, Complement Factor B, C-C Chemokine Receptor Type 2, Short Transient Receptor Potential Channel 5, Apolipoprotein L1, CD40 Ligand, and Others |
| Key Mechanisms of Action | Complement Factor D Inhibitor, Endothelin 1 Receptor Antagonist, Mannan Binding Lectin Serine Protease 2 Inhibitor, Tumor Necrosis Factor Ligand Superfamily Member 13 Inhibitor, Complement C3 Inhibitor, Complement Factor B Inhibitor, C-C Chemokine Receptor Type 2 Antagonist, Short Transient Receptor Potential Channel 5 Blocker, Apolipoprotein L1 Inhibitor, CD40 Ligand Inhibitor, and Others |
| Key Routes of Administration | Oral, Subcutaneous, Intravenous, Intravitreal, Intramuscular, Intravenous Drip, Nasogastric, and Parenteral |
| Key Molecule Type | Small Molecule, Monoclonal Antibody, Fusion Protein, Synthetic Peptide, Recombinant Protein, Antisense RNAi Oligonucleotide, Gene-Modified Cell Therapy, Polymer, Recombinant Enzyme, and Antibody |
| Major Companies | Chinook Therapeutics Inc, Alexion Pharmaceuticals Inc, Visterra Inc, Wuhan LL Science and Technology Development Co Ltd, Apellis Pharmaceuticals Inc, Goldfinch Bio Inc, Omeros Corp, Vertex Pharmaceuticals Inc, Anagenics Ltd, and Calliditas Therapeutics AB |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Glomerulonephritis (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Alexion Pharmaceuticals Inc
Algomedix Inc
Alnylam Pharmaceuticals Inc
Amyndas Pharmaceuticals LLC
Anagenics Ltd
Angion Biomedica Corp
Apellis Pharmaceuticals Inc
Argenx SE
Arrowhead Pharmaceuticals Inc
Bayer AG
BioCryst Pharmaceuticals Inc
Biogen Inc
Boehringer Ingelheim International GmbH
Cabaletta Bio Inc
Calliditas Therapeutics AB
Ceptur Therapeutics Inc
Certa Therapeutics Pty Ltd
ChemoCentryx Inc
Chinook Therapeutics Inc
Coegin Pharma AS
Cytodesign Inc
Delta 4 GmbH
DiaMedica Therapeutics Inc
Dimerix Ltd
Eledon Pharmaceuticals Inc
Eli Lilly and Co
Ergon Pharmaceuticals LLC
Generian Pharmaceuticals Inc
Goldfinch Bio Inc
HanAll Biopharma Co Ltd
Horizon Therapeutics Plc
IGAN Biosciences Inc
ImmunoWork LLC
Inmagene Biopharmaceuticals Ltd
InSilico Medicine
Integral Molecular Inc
INVENT Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
Jiangsu Hengrui Medicine Co Ltd
KeyMed Biosciences Inc
Mallinckrodt Plc
MorphoSys AG
Novartis AG
NovelMed Therapeutics Inc
Oak Hill Bio Inc
Omeros Corp
Oraxion Therapeutics Inc
Pfizer Inc
PlateletBio
Polyneuron Pharmaceuticals AG
Puretech Health Plc
Ra Pharmaceuticals Inc
Reata Pharmaceuticals Inc
RemeGen Co Ltd
River 3 Renal Corp
Rohto Pharmaceutical Co Ltd
Shanghai Alebund Pharmaceuticals Ltd
Shenzhen Evergreen Therapeutics Co Ltd
Slate Bio Inc
Sujana Biotech, LLC
Surrozen Inc
Takeda Pharmaceutical Co Ltd
Transcenta Holding Ltd
Travere Therapeutics Inc
Vera Therapeutics Inc
Vertex Pharmaceuticals Inc
Visterra Inc
Wuhan LL Science and Technology Development Co Ltd
ZyVersa Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Glomerulonephritis products market?
The key targets in the Glomerulonephritis pipeline products market are Complement Factor D, Endothelin 1 Receptor, Mannan Binding Lectin Serine Protease 2, Tumor Necrosis Factor Ligand Superfamily Member 13, Complement C3, Complement Factor B, C-C Chemokine Receptor Type 2, Short Transient Receptor Potential Channel 5, Apolipoprotein L1, CD40 Ligand, and others.
-
What are the key mechanisms of action in the Glomerulonephritis pipeline products market?
The key mechanisms of action in the Glomerulonephritis pipeline products market are Complement Factor D Inhibitor, Endothelin 1 Receptor Antagonist, Mannan Binding Lectin Serine Protease 2 Inhibitor, Tumor Necrosis Factor Ligand Superfamily Member 13 Inhibitor, Complement C3 Inhibitor, Complement Factor B Inhibitor, C-C Chemokine Receptor Type 2 Antagonist, Short Transient Receptor Potential Channel 5 Blocker, Apolipoprotein L1 Inhibitor, CD40 Ligand Inhibitor, and others.
-
What are the key routes of administration in the Glomerulonephritis pipeline products market?
The key routes of administration in the Glomerulonephritis pipeline products market are oral, subcutaneous, intravenous, intravitreal, intramuscular, intravenous drip, nasogastric, and parenteral.
-
What are the key molecule types in the Glomerulonephritis pipeline products market?
The key molecule types in the Glomerulonephritis pipeline products market are small molecule, monoclonal antibody, fusion protein, synthetic peptide, recombinant protein, antisense RNAi oligonucleotide, gene-modified cell therapy, polymer, recombinant enzyme, and antibody.
-
Which are the major companies in the Glomerulonephritis pipeline products market?
Some of the major companies in the Glomerulonephritis pipeline products market are Chinook Therapeutics Inc, Alexion Pharmaceuticals Inc, Visterra Inc, Wuhan LL Science and Technology Development Co Ltd, Apellis Pharmaceuticals Inc, Goldfinch Bio Inc, Omeros Corp, Vertex Pharmaceuticals Inc, Anagenics Ltd, and Calliditas Therapeutics AB.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Glomerulonephritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Genito Urinary System And Sex Hormones reports